These cellular alterations allow FGF23 to act on bronchial epithelial cells, which results in the activation of FGFR4/PLCγ/calcineurin/NFAT signaling and subsequent upregulation of IL-1β expression in COPD patients [203]. The gene discussed is FGF23; the disease is chronic obstructive pulmonary disease.